Search
Search
Show Description +
Learn more about OTT166 and how it's being developed as a noninvasive treatment to prevent or slow Diabetic Retinopathy.
Posted: 4/27/2023
Learn more about OTT166 and how it's being developed as a noninvasive treatment to prevent or slow Diabetic Retinopathy.
Posted: 4/27/2023
Current Practice and Future Options for Nonproliferative Diabetic Retinopathy
DR Research Roundup: Phase 2 and 3
Shifting the Paradigm
Current Practice and Future Options for Nonproliferative Diabetic Retinopathy
To find out more about the phase 2 DREAM study of OTT166 in eyes with diabetic retinopathy and how you can refer your patients, please contact the representative from Parexel, the CRO assisting OcuTerra in facilitating the DREAM study, listed below.
Learn MoreAbout Ocuterra
OcuTerra is led by a team with significant biotechnology entrepreneurial and ophthalmology drug development experience and supported by the field’s leading scientific and clinical advisors.
Visit us online: ocuterratx.com
Follow Ocuterra
© 2023 OcuTerra Therapeutics, Inc.
